retatrutide 2025 trial results Retatrutide approval: FDA status, clinical trial results, and when it could be available Eli Lilly infiltrates anti-obesity market

We speculate that a fraction of the purified receptor complex may bind Gs in the absence of the agonist

It remains an investigational medicinal product (IMP) and has not been granted a marketing authorisation by the MHRA or the EMA (MHRA medicines licensing database, accessed April 2025

Ann Intern Med 176(3):427429

Meanwhile, logos from the New York Times , Bloomberg and Forbes implied editorial coverage that at that point did not exist

The influence of nutrition on intestinal permeability and the microbiome in health and disease

1 2 Analysts have projected that the longer TRIUMPH-1 trial (80 weeks) could show weight loss exceeding 30%